KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $13,016.78. Following the transaction, the chief financial officer now owns 68,581 shares in the company, valued at approximately $523,273.03. The trade was a 2.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

KALA BIO Stock Up 2.1 %

KALA stock opened at $7.69 on Wednesday. The company has a market cap of $35.45 million, a PE ratio of -0.62 and a beta of -2.11. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO, Inc. has a 52 week low of $4.21 and a 52 week high of $9.25. The business has a 50-day simple moving average of $6.71 and a 200 day simple moving average of $6.32.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research report on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.